Recombinant Human CREG1, N-His

Description of Recombinant Human CREG1, N-His

Introduction

Recombinant Human CREG1, N-His is a protein that has been extensively studied for its potential as a drug target in various diseases. It is a recombinant form of the human CREG1 protein, which is a member of the Cysteine-rich secretory protein, antigen 5, and pathogenesis-related 1 (CAP) superfamily. This protein is highly conserved across different species and has been found to play a crucial role in various biological processes. In this article, we will explore the structure, activity, and potential applications of Recombinant Human CREG1, N-His as a drug target.

Structure of Recombinant Human CREG1, N-His

Recombinant Human CREG1, N-His is a 21-kDa protein that is composed of 189 amino acids. It has a similar structure to the native CREG1 protein, with a signal peptide at the N-terminus and a His-tag at the C-terminus. The protein has a unique three-dimensional structure, with three disulfide bonds that stabilize the protein. The crystal structure of Recombinant Human CREG1, N-His has been determined, revealing a globular fold with a central core of four β-strands surrounded by four α-helices.

Activity of this protein

The main activity of Recombinant Human CREG1, N-His is its ability to bind to and inhibit the activity of various growth factors, such as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and platelet-derived growth factor (PDGF). This binding is mediated by the cysteine-rich domain of the protein, which is highly conserved among the CAP superfamily members. By inhibiting the activity of these growth factors, Recombinant Human CREG1, N-His can regulate cell proliferation, differentiation, and migration.

In addition to its role as a growth factor inhibitor, Recombinant Human CREG1, N-His has also been shown to have anti-inflammatory properties. It can suppress the production of pro-inflammatory cytokines, such as TNF-α and IL-1β, and promote the secretion of anti-inflammatory cytokines, such as IL-10. This activity has been attributed to the ability of Recombinant Human CREG1, N-His to inhibit the NF-κB signaling pathway, a key regulator of inflammation.

Application as a Drug Target

The unique structure and activity of Recombinant Human CREG1, N-His make it a promising drug target for various diseases. Its ability to inhibit the activity of growth factors makes it a potential therapeutic agent for diseases characterized by excessive cell proliferation, such as cancer and fibrosis. In fact, studies have shown that Recombinant Human CREG1, N-His can inhibit the growth and migration of cancer cells in vitro and in animal models.

Moreover, the anti-inflammatory properties of Recombinant Human CREG1, N-His make it a potential treatment for inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease. Its ability to regulate the production of pro-inflammatory cytokines and inhibit the NF-κB signaling pathway makes it a promising candidate for these conditions.

In addition to its potential as a standalone therapy, Recombinant Human CREG1, N-His can also be used in combination with other drugs to enhance their efficacy. For example, studies have shown that combining Recombinant Human CREG1, N-His with chemotherapeutic agents can improve their anti-cancer activity.

Conclusion

In summary, Recombinant Human CREG1, N-His is a promising drug target with a unique structure and activity. Its ability to inhibit the activity of growth factors and regulate inflammation makes it a potential treatment for various diseases. Further research and clinical trials are needed to fully explore the potential of this protein as a therapeutic agent.